TANAMIN Digital Health Challenge Investor Day will be held on March 29th. The event will include startup pitch of four finalist startups selected at this partnership program and Mitsubishi Tanabe Pharma Corporation will share the progress/ results of the PoC with respective startup also the current activities and future vision of digital healthcare field. Please join us for find out their exciting journey!
<About TANAMIN Digital Health Challenge＞
Mitsubishi Chemical Group Corporation seeks to collaborate with startups in order to adopt novel technologies in healthcare that will improve the quality of life of patients and their families. The 6 months online program covers the following themes.
① Improve well-being of ALS patients and their families
② Digitalize Decentralized Clinical Trial (DCT)
③ Increase preventative vaccination in Japan
The 6 months online program will connect startups to the project teams of Mitsubishi Tanabe Pharma Corporation, in an effort to work toward mutually agreed upon goals.
TANAMIN Digital Health Challenge program detail:
15:50 Door Open
16:02 Greetings from Mitsubishi Tanabe Pharma Corporation
16:06 Introduction of TANAMIN Digital Health Challenge program
16:11 Introduction of startup finalists of TANAMIN Digital Health Challenge program
16:15 "Improve well-being of ALS patients and their families"- startup pitch and PoC progress/result introduction
16:47 "Digitalize Decentralized Clinical Trial (DCT)" - startup pitch and PoC progress/result introduction
17:03 "Increase preventative vaccination in Japan" - startup pitch and PoC progress/result introduction
17:19 Introduction of Mitsubishi Tanabe Pharma Corporation's DX activities and future vision of the TANAMIN Digital Health Challenge program
17:25 Greetings from Mitsubishi Chemical Group
17:28 Networking (offline venue only)
MinaCare Co., Ltd.
The company promotes businesses that invest in healthcare by combining the medical knowledge of medical professionals, medical data analysis, management planning, and medical policy networks. Specifically, the company provides consulting on prevention and health promotion strategies and supporting services for implementation, mainly to insurers with healthcare needs.
To help promote decentralized clinical trials, GattaCo's proprietary device simplifies the complex process of separating plasma from whole blood, an essential step in clinical testing. This also simplifies the testing of plasma components and the transport of validated samples.
A I Voice Platform "CoeFont" is developed with the concept to "provide a good voice, anytime, easily". The company provides AI voice services that are as close to the human voice as possible at a reasonable price, the service also includes to synthetic voice for individuals who have lost or may lose their voices due to illness.
The service leverages AI technology to guide patients to the appropriate medical institution and department according to their symptoms and assists physicians in early diagnosis. This will support quick and appropriate decision-making by both patients and specialists. In addition, the company is developing a service to help patients with ALS seek neurologists as early as possible.
2023/09/14(Thu) 09:00 (JST)